The purpose of this study is to evaluate the safety, tolerability, pharmacokinetics, and pharmacodynamics following increasing doses of 2 h (Part A) and 5 day (Part B) continuous IV infusions of BMS-962212 in healthy subjects across the expected pharmacodynamic dose range.
Ask a Question?
Ask your question and our customer service team will answer it as soon as they can. Questions that do not contain personal information may be posted to our help center to be of service to others
Please enter valid email address.
Please enter all required fields.